Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan Washington University School of Medicine, St Louis, Missouri Cleveland Clinic Foundation, Cleveland, Ohio Ohio State University Comprehensive Cancer Center, Columbus, Ohio Rhode Island Hospital, Providence, Rhode Island